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Abstract
Background: Cronkhite-Canada syndrome (CCS) is a rare non-inherited disorder, characterized by gastrointestinal
polyposis and ectodermal changes. The pathophysiology remains unclear. Treatment with corticosteroids is
considered the mainstay treatment because of its high efficacy. However, some patients have steroid-resistant CCS.
The therapeutic strategy for steroid-resistant CCS is not yet established. We report two cases with steroid-resistant
CCS that were effectively treated with cyclosporine (CyA). We evaluated the therapeutic strategy for steroid-resistant
CCS based on reviews of previous reports.
Case presentation: Our patients with CCS were first treated with prednisolone. No clinical response was noted,
and treatment with CyA was initiated. After beginning CyA treatment, both clinical symptoms and polyposis
markedly improved. Up to the present, 55 cases of CCS treated with corticosteroids and their response were
reported. Out of the 57 patients, including our 2 cases, 9 (16 %) did not respond clinically to corticosteroids.
In 7 of the 9 steroid-resistant cases, the prognosis after corticosteroids treatment was described. In 5 of the 7
steroid-resistant cases, immunosuppressive treatments induced remission. In 4 of these 5 cases, moreover, the
key drug of treatments was calcineurin inhibitor.
Conclusions: Treatment with calcineurin inhibitor, such as CyA, could be a potential option for steroid-resistant CCS.
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Background
Cronkhite-Canada syndrome (CCS), first reported by
Cronkhite and Canada in 1955 [1], is a rare non-
inherited disorder characterized by gastrointestinal
polyposis accompanied by malabsorption and ectoder-
mal changes, such as alopecia, onychodystrophy, and
hyperpigmentation.
The pathophysiology of CCS remains unclear, despite
many previous reports [1–5]. Because corticosteroid treat-
ment for CCS is reported to be highly effective, it is con-
sidered the mainstay treatment for CCS. A recent study
demonstrated the expression of autoimmune-related IgG4
antibody in CCS polyps [2]. The histological findings and
response to immunosuppressive treatments suggested that
immune response played an important role in the patho-
physiology of CCS, and that a part of CCS might be one
of IgG4-related disease. Although approximately 90 % of
patients with CCS respond to corticosteroids, however,
the remaining patients are refractory to corticosteroid
treatment [2]. The therapeutic strategy for steroid-
resistant CCS is not yet established. Here we report two
cases with steroid-resistant CCS that were effectively
treated with cyclosporine (CyA).
Case presentation
Case 1
A 75-year-old Japanese woman was admitted to our hos-
pital with watery diarrhea and dysgeusia for two months,
and alopecia for three weeks (Fig. 1a). Laboratory
findings included hypoproteinemia (albumin: 2.9 g/dl,
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cholinesterase: 186 U/l, total cholesterol: 117 mg/dl)
and pancytopenia (hemoglobin: 6.6 g/dl, platelet count:
1.9 × 104 /μl, white blood cell count: 2700 /μl). The
serum concentration of IgG and IgG4 (IgG 626 mg/dl,
IgG4 43.5 mg/dl) was normal. Endoscopic findings re-
vealed multiple reddish inflammatory polyps and
edematous adjacent mucosa in the stomach, duodenum,
terminal ileum, and colon (Fig. 2a and b). Histologic
findings of polyps revealed prominent cystic dilation of
the crypts and expanded inflamed lamina propria,
showing few IgG4-positive plasma cells in the polyps.
Moreover, bone marrow biopsy showed hypercellular-
ity, 0.3 % of blast cells and a normal karyotype. Based
on these clinical findings, CCS concomitant with mye-
lodysplastic syndrome (MDS) was diagnosed. MDS was
classified as refractory anemia according to French
American British classification, and the International
Prognostic Scoring System score was low. Despite
treatment with prednisolone (PSL) at a daily dose of
0.6 mg/kg (30 mg) for 4 weeks, no clinical response was
noted. Although the daily dose of PSL was increased to
1.0 mg/kg (50 mg), any clinical symptoms didn’t improve.
This patient was regarded as steroid-resistant CCS who
had ongoing active disease despite continuous treatment
with systemic corticosteroids referring to previous report
of steroid-refractory inflammatory bowel disease [6]. Con-
sidering the efficacy of CyA for MDS, CyA treatment was
initiated orally at a trough concentration of approxi-
mately 200 ng/ml. After beginning CyA treatment,
her symptoms and laboratory data, including pancyto-
penia, improved (Figs. 1b and 3a). PSL was gradually
tapering and discontinued at 9.5 months after initiating
PSL treatment. Endoscopic findings indicated the
disappearance of several gastrointestinal polyps 18 months
after beginning CyA treatment (Fig. 2c and d). For
52 months with CyA, there was no recurrence of symp-
toms, hypoproteinemia and polyps, and no incidence of
gastrointestinal cancer.
Case 2
A 50-year-old Japanese man presented with watery diar-
rhea and hyperpigmentation for two months, dysgeusia
and abdominal pain for two weeks, and a 10-kg weight
loss. Physical examination revealed onychatrophia and
hyperpigmentation. Laboratory data revealed hypopro-
teinemia (albumin: 2.7 g/dl, cholinesterase: 128 U/l, total
cholesterol: 108 mg/dl) and elevated IgG and IgG4
concentrations (IgG 1630 mg/dl, IgG4 638 mg/dl).
Endoscopic findings revealed numerous polyps in the
stomach, duodenum, and colon (Fig. 4a and b). Histo-
logic findings of the polyps indicated prominent cystic
dilated crypts and mixed inflammatory infiltrate with
eosinophils. Moreover, IgG4-positive plasma cells were
increased in the lamina propria (50 labeled cells per
high-power field [HPF]; Fig. 5a, b, c and d). CCS was
diagnosed based on those findings. Treated with PSL at
a daily dose of 0.6 mg/kg (40 mg) for 4 weeks, the serum
IgG4 concentration markedly decreased. However, his
abdominal symptoms worsened. Therefore, CyA treat-
ment was initiated intravenously at a blood concen-
tration of 400 ng/ml and PSL was tapered 4 weeks
after initiating PSL treatment referring to previous
report [7]. After beginning CyA treatment, his symp-
toms and laboratory data markedly improved (Fig. 3b).
CyA treatment was continued orally at a trough con-
centration of approximately 200 ng/ml, and PSL was
Fig. 1 Face photos in Case 1. a Alopecia of not only the scalp, but also the eyebrows, was observed on admission. b Alopecia improved
markedly after treatment with CyA
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Fig. 2 Endoscopic images in Case 1. The initial gastrointestinal endoscopy showed multiple reddish inflammatory polyps and edematous
adjacent mucosa in the stomach (a) and colon (b). The endoscopy 18 months after treatment with CyA revealed marked improvement in many
polyps in the stomach (c) and colon (d)
Fig. 3 Clinical course in Case 1 and Case 2. a In Case 1, treatment with PSL at a daily dose of 0.6 mg/kg (30 mg) was initiated. Because of no
clinical response to PSL 0.6 mg/kg, the dose of PSL was increased to at a daily dose of 1.0 mg/kg (50 mg). Because intensifying the dose of
PSL wasn’t effective, CyA treatment was induced. After beginning CyA treatment, her symptoms and laboratory data, including platelet count,
markedly improved, and blood transfusion was no longer needed. b In Case 2 with the high serum IgG4 level, treatment with PSL at a daily dose
of 0.6 mg/kg (40 mg) and total parenteral nutrition was initiated. After initiating PSL treatment, the serum IgG4 level decreased. However, clinical
symptoms were exacerbated and nutrition condition didn’t improve. Therefore, CyA treatment was induced. After beginning CyA treatment, his
symptoms and laboratory data markedly improved, and CyA treatment was continued orally at a trough level of 200 ng/ml. After beginning CyA
treatment, the serum IgG4 level decreased from 638 mg/dl to 97.0 mg/dl
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discontinued at 8.8 months after initiating PSL treat-
ment. Finally, the serum IgG4 concentration decreased
from 638 mg/dl to 97.0 mg/dl. Endoscopic findings re-
vealed a reduction in gastrointestinal polyps 8 months
after initiating CyA treatment (Fig. 4c and d). More-
over, few IgG4-positive plasma cells were found in
lamina propria of the polyps and adjacent mucosa
(Fig. 5e and f ).
Discussion
CCS is a progressive disease with various courses and a
5-year mortality rate was greater than 50 % [3]. To im-
prove the poor prognosis of CCS, various treatments
have been proposed, such as nutritional support, antibi-
otics, corticosteroids, immunomodulators, biologics, and
surgery [4]. Corticosteroids are reported to be highly
effective for treating CCS [2, 5]. The prognosis after
treatment with corticosteroids, however, is unknown.
In our cases, no clinical response was found despite
corticosteroids treatment, although the serum IgG4
concentration decreased after initiating corticosteroids
treatment in Case 2. CyA treatment could dramatically
improve clinical symptoms and endoscopic findings, and
maintain remission for a long time after discontinuing
corticosteroids. Therefore, CyA treatment was considered
effective for our both cases, although the possibility of the
delayed response to steroid could not be denied
completely.
A PubMed review of the English literature revealed 55
cases of CCS treated with corticosteroids for which the re-
sponse was clearly described. Of the 57 patients, including
our 2 cases, a symptomatic response was reported for 48
(84 %). On the other hand, the remaining 9 patients (16 %)
did not respond clinically to corticosteroids. (Table 1) [2, 4,
7–11]. Among the 9 steroid-resistant cases, 7 cases de-
scribed the clinical course after the treatment with cortico-
steroids and 2 cases didn’t. Out of these 7 patients, five
could achieve clinical remission by immunosuppressive
treatments (four patients: calcineurin inhibitor, one patient:
infliximab), one received colectomy, and last one died with-
out additional treatment.
An autoimmune mechanism has been more strongly
suggested to underlie the pathophysiology of CCS
since a recent study showed that IgG4-positive plasma
cells infiltrated the lamina propria in the polyps of
patients with CCS (positive IgG4 immunostaining [>5
cells/HPF] in 22 (52 %) of 42 polyps from 13 CCS
patients) [2]. A basic research reported that activation
Fig. 4 Endoscopic images in Case 2. The initial gastrointestinal endoscopy revealed numerous polyps in the stomach (a) and colon (b).
The number of gastric (c) and colon (d) polyps was markedly reduced 8 months after initiating CyA treatment
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of Toll-like receptors (TLRs) in basophils of patients
with IgG4-related diseases induced a large amount of
IgG4 by B cells, this enhancement of IgG4 production
was associated with B cell activating factor (BAFF)
and IL-13 [12]. In our Case 2, the high serum con-
centrations of IgG4 and the high number of IgG4-
positive plasma cells in gastrointestinal polyps were
detected before CyA treatments. Additionally, both
the serum concentrations of IgG4 and the number of
IgG4-positive plasma cells in gastrointestinal polyps could
improve after PSL and CyA treatments. Previous and our
data suggest that a part of CCS would be the IgG4-related
disease due to IgG4 producing B cells with BAFF and IL-
13 production through immune response, particularly in-
nate immune response.
Although those findings regarding IgG4 expression
weren’t found in our Case 1, concomitant MDS was
observed in our Case 1. Previously, Suzuki et al. also re-
ported a CCS case associated with MDS [13]. The inci-
dence rate of MDS in CCS patients was unclear, whereas
several retrospective studies and a recent cohort study
have demonstrated the high incidence rate (10–28 %) of
Fig. 5 Histologic findings of the colonic polyp biopsy specimen in Case 2. Histologic findings demonstrated the prominent cystic dilation of the
crypts (a) (hematoxylin and eosin stain; magnification × 40). Moreover, a mixed inflammatory infiltrate with prominent eosinophils was found (b)
(hematoxylin and eosin stain; magnification × 400). IgG-positive plasma cells numbered 60/HPF (c) (IgG-immunostaining; magnification × 400). In
the same field, the high number of IgG4-positive plasma cells was found (50 labeled cells per HPF) (83 % IgG4/IgG plasma cells) (d) (IgG4-immu-
nostaining; magnification × 400). Few IgG- and IgG4-positive plasma cells were found after treatment with CyA (e) (IgG-immunostaining; magnifi-
cation × 400), (f) (IgG4-immunostaining; magnification × 400)
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autoimmune diseases, such as hypothyroidism and
rheumatoid arthritis, in patients with MDS [14–17].
Thus, there is the strong association between auto-
immune diseases and MDS. Surprisingly, this cohort
study reported that MDS patients with autoimmune dis-
eases had significantly better clinical outcome including
overall survival rate and leukemia transformation rate
compared to those without autoimmune diseases [17].
In our Case 1, MDS concomitant with CCS was classi-
fied as low risk based on the International Prognostic
Scoring System score, and the prognosis was expected to
be good. These data also suggested that CCS might be
autoimmune disease. Furthermore, aggressive immuno-
suppressive treatments in MDS with autoimmune dis-
eases were reported to be effective for not only
controlling autoimmune phenomena but also leading to
hematological response [14]. Taking these data into ac-
count, immunosuppressive treatments, particularly CyA,
would be reasonable for CCS concomitant with MDS,
like our Case 1.
According to those data, the immunological dis-
order would be involving in the pathophysiology of
CCS. Therefore, immunosuppressive treatments with
calcineurin inhibitor, such as CyA, should be consid-
ered as a treatment for patients with steroid-resistant
CCS, although our gastroenterologists need pay atten-
tion to the risk of adverse events, such as severe
infection and malignancies.
Conclusion
We report that CyA treatment was effective for two pa-
tients with steroid-resistant CCS, and suggest that the
treatment with calcineurin inhibitor, such as CyA, could
be a therapeutic option for steroid-resistant CCS.
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1 57/M Corticosteroids Azathioprine
Ileocecal resection
Infliximab Infliximab 36 Symptom: Remission Polyp:
Remission
[4] /2014
2 71/M Prednisolone Cyclosporine Azathioprine 23 Symptom: Remission Polyp:
ND
[7] /2014
3 42/M Prednisolone Colectomy nothing 6 Symptom: Remission Polyp:
Remission
[8] /2013
4 ND Prednisolone ECP ND ND Symptom: ND Polyp: ND [2] /2012
5 50/M Prednisolone Colectomy ND ND Symptom: ND Polyp: ND [9] /2012
6 80/M Prednisolone Nothing Dead [10] /2008
7 44/M Prednisolone Tacrolimus
Azathioprine
Azathioprine 18 Symptom: Remission Polyp:
Remission
[11] /2006
8 75/F Prednisolone Cyclosporine Cyclosporine 52 Symptom: Remission Polyp:
Remission
Case1
9 50/M Prednisolone Cyclosporine Cyclosporine 8 Symptom: Remission Polyp:
Remission
Case2
ND not described, ECP endoscopic cyclophotocoagulation
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